Millennium, a division of the Takeda Oncology Company in Japan, is a leading biopharmaceutical company based in Cambridge, Massachuesets. Millenium markets VELCADE, a proteasome inhibitor which is primarily used in multiple myeloma patients.

But the company does’t focus soly on multiple myeloma research. Here is a part of their Thursday “Curtainraiser” ASH (American Society of Hematology) Preview Press Release about lymphoma and leukemia research:

Non-Hodgkin’s Lymphoma

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naïve or –Sensitive, Follicular Lymphoma


Presenter: Bertrand Coiffier, M.D., Hospices Civils de Lyon, Pierre-Benite, France
Abstract #857: Oral Presentation, Monday, December 6, 7:15 pm ET


A randomized, Phase III, open-label international trial compared VELCADE and rituximab to rituximab alone in relapsed follicular lymphoma.  Endpoints included progression free survival, response rate including complete response, duration of response, time to progression, safety and tolerability.

Oncology Pipeline
The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study


Presenter: Ronan T. Swords, M.D., University of Texas Health Science Center, San Antonio, Texas
Abstract #658: Oral Presentation, Monday, December 6, 5:15 pm ET


This is a Phase I, open-label, multi-center study of MLN4924 in two hematologic malignancies.  Endpoints included safety, tolerability, determination of maximum tolerated dose and establishment of Phase II dosing.

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma


Presenter: Robert Chen, M.D., City of Hope National Medical Center, Duarte, California
Abstract #283: Oral Presentation, Monday, December 6, 7:00 am ET


This pivotal, single-arm, multi-center study examined the efficacy and safety of single-agent brentuximab vedotin in relapsed or refractory post autologous stem cell transplantation Hodgkin lymphoma.  Endpoints included response rate, progression free survival, complete response rate, overall survival and duration of response.  Response assessments by an independent review facility were based on the rigorous and internationally established Revised Response Criteria for Malignant Lymphoma (Cheson, 2007)

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma


Presenter: Andrei Shustov, M.D., University of Washington Medical Center, Seattle, Washington
Abstract #961: Oral Presentation, Tuesday, December 7, 7:30 am ET


A single-arm, Phase II multi-center study to determine efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.  Endpoints included objective response rate, progression free survival, complete response rate, overall survival and duration of response.
Response assessments by an independent review facility were based on the rigorous and internationally established Revised Response Criteria for Malignant Lymphoma (Cheson, 2007)

Monday I wrote a story about brentuximab vedotin on this vary site:  More About Experimental Hodgkin’s Lymphoma Chemo Breakthrough: Brentuximab Vedotin.

I will be at this year’s ASH conference in Orlando.  You can read my thoughts about this year’s meetings, along with my impressions of last year’s ASH on my multiplemyelomablog site:  Pre-American Society Of Hematology (ASH) News Starting To Break.

I will be covering lots of blood cancer news over the next three weeks.  Not to worry, solid tumor fans–I won’t forget about you.  Important studies and articles about cancer nutrition and non-blood related cancers don’t stop just because ASH looms on the horizon.  I will make sure ASH related news doesn’t overshadow other helpful or important topics.  (See today’s second article about proton therapy.)

Feel good and keep smiling!  Pat

Leave a Reply